NASDAQ
ARDX

Ardelyx Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Ardelyx Inc Stock Price

Vitals

Today's Low:
$4.66
Today's High:
$4.9
Open Price:
$4.77
52W Low:
$0.49
52W High:
$4.16
Prev. Close:
$4.73
Volume:
4124524

Company Statistics

Market Cap.:
$829.07 million
Book Value:
0.495
Revenue TTM:
$52.16 million
Operating Margin TTM:
-110.36%
Gross Profit TTM:
$15.54 million
Profit Margin:
-128.85%
Return on Assets TTM:
-21.16%
Return on Equity TTM:
-74.28%

Company Profile

Ardelyx Inc had its IPO on 2014-06-19 under the ticker symbol ARDX.

The company operates in the Healthcare sector and Biotechnology industry. Ardelyx Inc has a staff strength of 0 employees.

Stock update

Shares of Ardelyx Inc opened at $4.77 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $4.66 - $4.9, and closed at $4.83.

This is a +2.11% increase from the previous day's closing price.

A total volume of 4,124,524 shares were traded at the close of the day’s session.

In the last one week, shares of Ardelyx Inc have increased by +0.21%.

Ardelyx Inc's Key Ratios

Ardelyx Inc has a market cap of $829.07 million, indicating a price to book ratio of 5.5233 and a price to sales ratio of 39.5354.

In the last 12-months Ardelyx Inc’s revenue was $52.16 million with a gross profit of $15.54 million and an EBITDA of $-56415000. The EBITDA ratio measures Ardelyx Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Ardelyx Inc’s operating margin was -110.36% while its return on assets stood at -21.16% with a return of equity of -74.28%.

In Q4, Ardelyx Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 4193.3%.

Ardelyx Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG
-0.08

Its diluted EPS in the last 12-months stands at $-1.14 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of -0.08. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Ardelyx Inc’s profitability.

Ardelyx Inc stock is trading at a EV to sales ratio of 35.063 and a EV to EBITDA ratio of -2.8787. Its price to sales ratio in the trailing 12-months stood at 39.5354.

Ardelyx Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$190.07 million
Total Liabilities
$65.60 million
Operating Cash Flow
$1.44 million
Capital Expenditure
$55000
Dividend Payout Ratio
0%

Ardelyx Inc ended 2024 with $190.07 million in total assets and $0 in total liabilities. Its intangible assets were valued at $190.07 million while shareholder equity stood at $98.33 million.

Ardelyx Inc ended 2024 with $0 in deferred long-term liabilities, $65.60 million in other current liabilities, 20000.00 in common stock, $-780137000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $96.14 million and cash and short-term investments were $123.91 million. The company’s total short-term debt was $30,605,000 while long-term debt stood at $0.

Ardelyx Inc’s total current assets stands at $153.60 million while long-term investments were $0 and short-term investments were $27.77 million. Its net receivables were $7.73 million compared to accounts payable of $10.86 million and inventory worth $3.28 million.

In 2024, Ardelyx Inc's operating cash flow was $1.44 million while its capital expenditure stood at $55000.

Comparatively, Ardelyx Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$4.83
52-Week High
$4.16
52-Week Low
$0.49
Analyst Target Price
$6.87

Ardelyx Inc stock is currently trading at $4.83 per share. It touched a 52-week high of $4.16 and a 52-week low of $4.16. Analysts tracking the stock have a 12-month average target price of $6.87.

Its 50-day moving average was $3.84 and 200-day moving average was $3.54 The short ratio stood at 1.68 indicating a short percent outstanding of 0%.

Around 150.5% of the company’s stock are held by insiders while 3966.4% are held by institutions.

Frequently Asked Questions About Ardelyx Inc

The stock symbol (also called stock or share ticker) of Ardelyx Inc is ARDX

The IPO of Ardelyx Inc took place on 2014-06-19

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
FBR Limited (FBRKF)
$0.02
0
0%
BASF SE ADR (BASFY)
$12.06
0.21
+1.77%
Aptech Limited (532475)
$288.35
-17.9
-5.84%
$78.43
-0.47
-0.6%
$19.98
-0.04
-0.2%
$0.25
-0.01
-1.96%
$1.66
-0.15
-8.29%
$92.06
-5.37
-5.51%
$28.96
-3.38
-10.45%
PB Fintech Limited (POLICYBZR)
$784.45
-10.9
-1.37%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Address

400 Fifth Avenue, Waltham, MA, United States, 02451